510(k) clearance for Picker's ACQPLAN :
This article was originally published in Clinica
The FDA has cleared Picker International's ACQPLAN three dimensional radiation therapy planning (RTP) system for marketing in the US. The device calculates treatment dose in monitor units and can also be used with the company's ACQSIM CT simulator, eliminating the need to transfer CT simulation images to remote RTP workstations. With the integrated ACQPLAN/ACQSIM system, the patient only needs to be scanned for around two minutes, long enough to acquire basic datasets. The whole simulation and three-dimensional RTP process is then carried out using this "virtual" CT data. This method increases patient's comfort as well as CT scanner throughput hence reduces costs, said Picker.
You may also be interested in...
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.
Pharmaceutical companies struggling to keep up with coronavirus-related supply chain havoc asked to keep the US regulator informed as situation unfolds.